Semantic Scholar uses AI to extract papers important to this topic.
Amprenavir is an HIV-1 protease inhibitor, the first in vitro activity studies of which were published in 1995. During in vivo… Expand A series of P1-substituted biaryl amprenavir derivatives was designed and synthesized. These compounds were evaluated for enzyme… Expand OBJECTIVES
The purpose of this study was to evaluate the steady-state pharmacokinetics of amprenavir and ritonavir in HIV… Expand BACKGROUND
Emerging evidence suggests that female sex may be associated with increased risk of developing antiretroviral… Expand ABSTRACT The protease inhibitor (PI) ritonavir is used as a strong inhibitor of cytochrome P450 3A4, which boosts the activities… Expand Starting from the chemical structure of the recent FDA-approved anti-HIV drug Amprenavir (Agenerase), a potent HIV-protease… Expand ABSTRACT In this crossover study in 12 healthy volunteers, coadministration of amprenavir (1,200 mg; single dose) with grapefruit… Expand ABSTRACT In a dose-ranging study of amprenavir (formerly 141W94), an inhibitor of the protease enzyme of human immunodeficiency… Expand UNLABELLED
The virological/immunological efficacy of amprenavir-containing combination regimens has been evaluated in a small… Expand